XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2023
Apr. 26, 2024
Jun. 30, 2023
Document Information [Line Items]      
Document Type 10-K/A    
Document Period End Date Dec. 31, 2023    
Document Annual Report true    
Document Transition Report false    
Entity File Number 000-50626    
Entity Registrant Name Cyclacel Pharmaceuticals, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 91-1707622    
Entity Address, Address Line One 200 Connell Drive    
Entity Address, Address Line Two Suite 1500    
Entity Address, City or Town Berkeley Heights    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07922    
City Area Code 908    
Local Phone Number 517-7330    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001130166    
Amendment Flag true    
Amendment Description This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the fiscal year ended December 31, 2023, as originally filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2024 (the “Original 10-K”). The purpose of this Amendment is to include information required by Part III of the Annual Report on Form 10-K that was intentionally omitted from Part III of the Original 10-K. In addition, this Amendment amends Item 15 of Part IV of the Original 10-K to update the exhibit list and to include new certifications by our principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Public Float     $ 5,622,362
Entity Common Stock, Shares Outstanding   1,318,257  
ICFR Auditor Attestation Flag false    
Common Stock      
Document Information [Line Items]      
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol CYCC    
Security Exchange Name NASDAQ    
Preferred Stock      
Document Information [Line Items]      
Title of 12(b) Security Preferred Stock, $0.001 par value    
Trading Symbol CYCCP    
Security Exchange Name NASDAQ